Skip to Content
Read about colorectal cancer treatments here >

Regorafenib Pregnancy and Breastfeeding Warnings

Regorafenib is also known as: Stivarga

Regorafenib Pregnancy Warnings

Embryo-fetal development animal studies observed a total loss of pregnancy at doses as low as 1 to 1.6 mg/kg. Animal studies also reported delayed ossification in fetuses with dose-dependent increases in skeletal malformations, cardiovascular malformations, external abnormalities, diaphragmatic hernia, and dilation of the renal pelvis. In addition, ventricular septal defects and significant adverse effects on the urinary system (including missing kidney/ureter; small, deformed and malpositioned kidney; and hydronephrosis) were found. Results from animal studies indicated that regorafenib can impair male (tubular atrophy and degeneration in the testes, atrophy in the seminal vesicle, and cellular debris and oligospermia in the epididymides) and female (necrotic corpora lutea in the ovaries) fertility. There are no controlled data in human pregnancy. FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

FDA pregnancy category: D Use of regorafenib should be avoided. Females and males should use adequate methods of contraception during treatment and for 2 months after the last dose.

See references

Regorafenib Breastfeeding Warnings

A decision should be made to discontinue breast-feeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Yes The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Stivarga (regorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.

References for breastfeeding information

  1. "Product Information. Stivarga (regorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.